Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies

Sun,Xu; Ma,Xueman; Li,Qiwei; Yang,Yong; Xu,Xiaolong; Sun,Jiaqi; Yu,Mingwei; Cao,Kexin; Yang,Lin; Yang,Guowang; Zhang,Ganlin; Wang,Xiaomin

doi:10.3892/ijmm.2018.3654

Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies

Authors:
- Xu Sun
- Xueman Ma
- Qiwei Li
- Yong Yang
- Xiaolong Xu
- Jiaqi Sun
- Mingwei Yu
- Kexin Cao
- Lin Yang
- Guowang Yang
- Ganlin Zhang
- Xiaomin Wang
View Affiliations

Affiliations: Department of Oncology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, P.R. China, Department of Oncology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, P.R. China
Published online on: May 2, 2018 https://doi.org/10.3892/ijmm.2018.3654
Pages: 811-820
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fisetin, a natural flavonoid found in a variety of edible and medical plants, has been suggested to inhibit the proliferation of various tumor cells and to induce apoptosis. However, the effects of fisetin on breast cancer have rarely been reported and the underlying mechanism is still undefined. The present study explored the anti‑cancer effects of fisetin on mammary carcinoma cells and the underlying mechanisms. Following treatment with fisetin, viability of 4T1, MCF‑7 and MDA‑MB‑231 cells were measured by MTT assay. The inhibitory effects of fisetin on proliferation, migration and invasion were evaluated in 4T1 cells using proliferation array, wound‑healing assay, and HUV‑EC‑C‑cell barrier based on electrical cell‑substrate impedance sensing platform. Cell apoptosis was analyzed by flow cytometry, and western blotting analysis was performed to identify target molecules. A 4T1 orthotopic mammary tumor model was used to assess the fisetin‑inhibition on tumor growth in vivo. Test kits were used to examine the liver and kidney function of tumor‑bearing mice. The results suggest that fisetin suppressed the proliferation of breast cancer cells, suppressed the metastasis and invasiveness of 4T1 cells, and induced the apoptosis of 4T1 cells in vitro. The potent anti‑cancer effect of fisetin was associated with the regulation of the phosphatidylinositol‑3‑kinase/protein kinase B/mammalian target of rapamycin pathway. In vivo experiments demonstrated that fisetin suppressed the growth of 4T1 cell‑derived orthotopic breast tumors and enhanced tumor cell apoptosis, and the evaluated alanine amino transferase and aspartate amino transferase levels in serum of tumor‑bearing mice suggested that fisetin may lead to side effects on liver biochemical function. The present study confirms that fisetin exerted an anti‑mammary carcinoma effect. However, in vivo experiments also revealed that fisetin had low solubility and low bioavailability. Further investigation is required to determine the clinical value of fisetin.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Gemignani ML and Hetzel DJ: Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer. Gynecol Oncol. 147:153–157. 2017. View Article : Google Scholar : PubMed/NCBI
4	Wander SA, Mayer EL and Burstein HJ: Blocking the cycle: Cyclin-dependent kinase 4/6 inhibitors in metastatic, hormone receptor-positive breast cancer. J Clin Oncol. 35:2866–2870. 2017. View Article : Google Scholar : PubMed/NCBI
5	Guerrero-Zotano AL and Arteaga CL: Neoadjuvant trials in ER⁺ breast cancer: A tool for acceleration of drug development and discovery. Cancer Discov. 7:561–574. 2017. View Article : Google Scholar : PubMed/NCBI
6	Hu X, Huang W and Fan M: Emerging therapies for breast cancer. J Hematol Oncol. 10:982017. View Article : Google Scholar : PubMed/NCBI
7	Shachar SS, Jolly TA, Jones E and Muss HB: Management of triple-negative breast cancer in older patients: How is it different? Oncology (Williston Park). 32:58–63. 2018.
8	Lee A and Djamgoz MBA: Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 62:110–122. 2018. View Article : Google Scholar
9	Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, Lobie PE, Goh BC, Lim LHK, Hartman M, et al: Triple negative breast cancer in Asia: An insider's view. Cancer Treat Rev. 62:29–38. 2018. View Article : Google Scholar
10	Chao J, Dai Y, Verpoorte R, Lam W, Cheng YC, Pao LH, Zhang W and Chen S: Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochem Pharmacol. 139:94–104. 2017. View Article : Google Scholar : PubMed/NCBI
11	Goyal S, Gupta N, Chatterjee S and Nimesh S: Natural plant extracts as potential therapeutic agents for the treatment of cancer. Curr Top Med Chem. 17:96–106. 2017. View Article : Google Scholar
12	Sun X, Zhang X, Nian JY, Guo J, Yin Y, Zhang GL, Yu MW, Zhang Y, Wang XM, Yang GW, et al: Chinese herbal medicine as adjunctive therapy to chemotherapy for breast cancer: A systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016:32819682016. View Article : Google Scholar : PubMed/NCBI
13	Khan N, Syed DN, Ahmad N and Mukhtar H: Fisetin: A dietary antioxidant for health promotion. Antioxid Redox Signal. 19:151–162. 2013. View Article : Google Scholar :
14	Hodek P, Trefil P and Stiborová M: Flavonoids-potent and versatile biologically active compounds interacting with cytochromes 450. Chem Biol Interact. 139:1–21. 2002. View Article : Google Scholar : PubMed/NCBI
15	Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, Choi KC, Kim J, Han SK, Lee KY, et al: Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochimic Biophys Acta. 1726:309–316. 2005. View Article : Google Scholar
16	Moon YJ, Wang X and Morris ME: Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro. 20:187–210. 2006. View Article : Google Scholar
17	Wang G, Wang JJ, Guan R, Du L, Gao J and Fu XL: Strategies to target glucose metabolism in tumor microenvironment on cancer by flavonoids. Nutr Cancer. 69:534–554. 2017. View Article : Google Scholar : PubMed/NCBI
18	George VC, Dellaire G and Rupasinghe HPV: Plant flavonoids in cancer chemoprevention: Role in genome stability. J Nutr Biochem. 45:1–14. 2017. View Article : Google Scholar
19	Magne Nde CB, Zingue S, Winter E, Creczynski-Pasa TB, Michel T, Fernandez X, Njamen D and Clyne C: Flavonoids, breast cancer chemopreventive and/or chemotherapeutic agents. Curr Med Chem. 22:3434–3446. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zamora-Ros R, Agudo A, Lujan-Barroso L, Luján-Barroso L, Romieu I, Ferrari P, Knaze V, Bueno-de-Mesquita HB, Leenders M, Travis RC, et al: Dietary flavonoid and lignan intake and gastric adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 96:1398–1408. 2012. View Article : Google Scholar : PubMed/NCBI
21	Frankenfeld CL, Cerhan JR, Cozen W, Davis S, Schenk M, Morton LM, Hartge P and Ward MH: Dietary flavonoid intake and non-Hodgkin lymphoma risk. Am J Clin Nutr. 87:1439–1445. 2008. View Article : Google Scholar : PubMed/NCBI
22	Syed DN, Adhami VM, Khan MI and Mukhtar H: Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 13:995–1001. 2013. View Article : Google Scholar : PubMed/NCBI
23	Khan N, Afaq F, Khusro FH, Mustafa Adhami V, Suh Y and Mukhtar H: Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer. 130:1695–1705. 2012. View Article : Google Scholar
24	Liao YC, Shih YW, Chao CH, Lee XY and Chiang TA: Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549. J Agric Food Chem. 57:8933–8941. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ravichandran N, Suresh G, Ramesh B and Siva GV: Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Food Chem Toxicol. 49:1141–1147. 2011. View Article : Google Scholar : PubMed/NCBI
26	Touil YS, Seguin J, Scherman D and Chabot GG: Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol. 68:445–455. 2011. View Article : Google Scholar
27	Syed DN, Afaq F, Maddodi N, Johnson JJ, Sarfaraz S, Ahmad A, Setaluri V and Mukhtar H: Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J Invest Dermatol. 131:1291–1299. 2011. View Article : Google Scholar : PubMed/NCBI
28	Murtaza I, Adhami VM, Hafeez BB, Saleem M and Mukhtar H: Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer. 125:2465–2473. 2009. View Article : Google Scholar : PubMed/NCBI
29	Costa RLB, Han HS and Gradishar WJ: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res Treat. 2018. View Article : Google Scholar : PubMed/NCBI
30	Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G and Giuliano M: PI3K/mTOR inhibitors in the treatment of luminal breast cancer. Why, when and to whom? Breast Care. 12:290–294. 2017. View Article : Google Scholar : PubMed/NCBI
31	Guerrero-Zotano A, Mayer IA and Arteaga CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016. View Article : Google Scholar : PubMed/NCBI
32	Arif H, Sohail A, Farhan M, Rehman AA, Ahmad A and Hadi SM: Flavonoids-induced redox cycling of copper ions leads to generation of reactive oxygen species: A potential role in cancer chemoprevention. Int J Biol Macromol. 106:569–578. 2018. View Article : Google Scholar
33	Ghosh P, Singha Roy A, Chaudhury S, Jana SK, Chaudhury K and Dasgupta S: Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity. Int J Biol Macromol. 86:408–417. 2016. View Article : Google Scholar : PubMed/NCBI
34	Noh EM, Park YJ, Kim JM, Kim MS, Kim HR, Song HK, Hong OY, So HS, Yang SH, Kim JS, et al: Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways. Eur J Pharmacol. 764:79–86. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kadari A, Gudem S, Kulhari H, Bhandi MM, Borkar RM, Kolapalli VR and Sistla R: Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles. Drug Deliv. 24:224–232. 2017. View Article : Google Scholar : PubMed/NCBI
36	Yang PM, Tseng HH, Peng CW, Chen WS and Chiu SJ: Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagy. Int J Oncol. 40:469–478. 2012.
37	Smith ML, Murphy K, Doucette CD, Greenshields AL and Hoskin DW: The dietary flavonoid fisetin causes cell cycle arrest, caspase-dependent apoptosis, and enhanced cytotoxicity of chemotherapeutic drugs in triple-negative breast cancer cells. J Cell Biochem. 117:1913–1925. 2016. View Article : Google Scholar : PubMed/NCBI
38	Wang L, Zhang DZ and Wang YX: Bioflavonoid fisetin loaded α-tocopherol-poly(lactic acid)-based polymeric micelles for enhanced anticancer efficacy in breast cancers. Pharm Res. 34:453–461. 2017. View Article : Google Scholar
39	Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM and Sharma D: Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via trans-activation of epidermal growth factor receptor. Cancer Res. 68:9712–9722. 2008. View Article : Google Scholar : PubMed/NCBI
40	Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67:2497–2507. 2007. View Article : Google Scholar : PubMed/NCBI
41	Zhang Y, Zhang GL, Sun X, Cao KX, Shang YW, Gong MX, Ma C, Nan N, Li JP, Yu MW, et al: Gubenyiliu II inhibits breast tumor growth and metastasis associated with decreased hepa-ranase expression and phosphorylation of erk and akt pathways. Molecules. 22:E7872017. View Article : Google Scholar
42	Sun JQ, Zhang GL, Zhang Y, Nan N, Sun X, Yu MW, Wang H, Li JP and Wang XM: Spatholobus suberectus column extract inhibits estrogen receptor positive breast cancer via suppressing ER MAPK PI3K/AKT pathway. Evid Based Complement Alternat Med. 2016:29343402016. View Article : Google Scholar
43	National Research Council (US) Committee: Guide for the care and use of laboratory animals. 8th. Washington (DC): 2011
44	Zhang Y, Zhang GL, Sun X, Cao KX, Ma C, Nan N, Yang GW, Yu MW and Wang XM: Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncology Lett. 15:6233–6240. 2018.
45	Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T and Contag PR: Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis. 20:733–744. 2003. View Article : Google Scholar
46	Lien EC, Dibble CC and Toker A: PI3K signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71. 2017. View Article : Google Scholar : PubMed/NCBI
47	Rodgers SJ, Ferguson DT, Mitchell CA and Ooms LM: Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci Rep. 37:2017. View Article : Google Scholar : PubMed/NCBI
48	Carvalho S and Schmitt F: Potential role of PI3K inhibitors in the treatment of breast cancer. Future Oncol. 6:1251–1263. 2010. View Article : Google Scholar : PubMed/NCBI
49	Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO and Green AR: PIK3C A expression in invasive breast cancer: A biomarker of poor prognosis. Breast Cancer Res Treat. 122:45–53. 2010. View Article : Google Scholar
50	López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA and Sutherland RL: PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 126:1121–1131. 2010. View Article : Google Scholar
51	Rychahou PG, Jackson LN, Silva SR, Rajaraman S and Evers BM: Targeted molecular therapy of the PI3K pathway: Therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg. 243:833–842. 2006. View Article : Google Scholar : PubMed/NCBI
52	Seguin J, Brullé L, Boyer R, Lu YM, Ramos Romano M, Touil YS, Scherman D, Bessodes M, Mignet N and Chabot GG: Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm. 444:146–154. 2013. View Article : Google Scholar : PubMed/NCBI